5.02% -0.1174

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA) 最新ニュース

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA) 最新ニュース

A new trading data show Taysha Gene Therapies Inc (TSHA) is showing positive returns. - SETE News

Taysha Gene Therapies Inc’s results are impressive - US Post News

Tay-Sachs Disease Market to Witness Growth by 2032 | Companies - openPR

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - Knox Daily

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Class Attys Vie To Lead Drug Co. Insider Trading Suit In Del. - Law360

Stock Surge: Taysha Gene Therapies Inc (TSHA) Closes at 2.07, Marking a 0.49 Increase/Decrease - The Dwinnex

Does Taysha Gene Therapies Inc (TSHA) offer a good opportunity for investors? - SETE News

Rett Syndrome Market Expected to Experience Major Growth - openPR

Checking in on Taysha Gene Therapies Inc (TSHA) after recent insiders movement - Knox Daily

Giant Axonal Neuropathy Market Growth to Accelerate in Forecast - openPR

Analytical Overview: Taysha Gene Therapies Inc (TSHA)’s Ratios Tell a Financial Story - The Dwinnex

A closer look at Taysha Gene Therapies Inc (TSHA)’s stock price trends - US Post News

Its Stock Has Paid Off Big Time For Taysha Gene Therapies Inc - SETE News

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Price Target from Analysts - MarketBeat

TSHA (Taysha Gene Therapies) Enterprise Value : $344.05 Mil (As of Aug. 20, 2024) - GuruFocus.com

TSHA (Taysha Gene Therapies) Cash From Discontinued Investi - GuruFocus.com

Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat

Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $6.00 - Defense World

Cantor Fitzgerald Brokers Raise Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Taysha Gene Therapies, Inc. to Post FY2024 Earnings of ($0.34) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TSHA) - MarketBeat

BMO maintains Outperform on Taysha Gene By Investing.com - Investing.com Canada

Canaccord sees regulatory engagement boosting Taysha Gene stock outlook By Investing.com - Investing.com Canada

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Lowered to $6.00 at Canaccord Genuity Group - MarketBeat

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - Defense World

Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $6.00 - Defense World

Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan Capital - Defense World

Taysha Gene Therapies' (TSHA) Buy Rating Reaffirmed at Chardan Capital - MarketBeat

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Vanguard Group Inc. Sells 278,153 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2024 Earnings Call Transcript - Insider Monkey

Vanguard Group Inc. Trims Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Taysha Gene Therapies Inc (TSHA) Q2 2024 Earnings Call Transcrip - GuruFocus.com

Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $6.00 - MarketBeat

Earnings call: Taysha Gene Therapies reports progress on Rett Syndrome trial - Investing.com

Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights - Benzinga

TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript - Seeking Alpha

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates - MSN

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance

Taysha Gene Therapies (TSHA) to Release Earnings on Monday - Defense World

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

Taysha Gene Therapies (TSHA) to Release Earnings on Monday - MarketBeat

Market Watch: Taysha Gene Therapies Inc (TSHA)’s Noteworthy Drop, Closing at 2.02 - The Dwinnex

Taysha Gene Therapies to Release Second Quarter 2024 - GlobeNewswire

Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 - StockTitan

TSHA Stock Sees Decline of Approximately -4.85% in Last Five Days - Knox Daily

Financial Metrics Exploration: Understanding Taysha Gene Therapies Inc (TSHA) Through Ratios - The Dwinnex

Taysha Gene Therapies Inc (TSHA) Performance and Fundamentals Dashboard tells a completely different story - SETE News

Acadian Asset Management LLC Has $75,000 Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Acadian Asset Management LLC - MarketBeat

A year in review: Taysha Gene Therapies Inc (TSHA)’s performance in the last year - US Post News

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of “Buy” by Brokerages - Defense World

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Analysts - MarketBeat

TSHAに似た銘柄